1887

Journal of Medical Microbiology logo

Volume 71, Issue 10

Pharmacodynamics of colistin resistance in carbapenemase-producing : the double-edged sword of heteroresistance and adaptive resistance No Access

Abstract

The presence of heteroresistant subpopulations and the development of resistance during drug exposure (adaptive resistance) limits colistin’s efficacy against carbapenemase-producing (CP-Kp) isolates.

. The pharmacokinetic/pharmacodynamic (PK/PD) characteristics of both types of colistin resistance against CP-Kp are unknown.

We therefore studied the PK/PD characteristics of colistin resistance in an PK/PD model simulating clinical colistin exposures.

Two clinical isolates, one non-CP-Kp and one CP-Kp, with colistin MICs of 0.5–1 mg l at a final inoculum of 10 c.f.u. ml were used in an PK/PD dialysis/diffusion closed model simulating 4.5 MU q12h and 3 MU q8h clinical dosing regimens. Heteroresistant (HRS, bacteria with stable high-level resistance present before drug exposure) and adaptive resistant (ARS, bacteria with reversible low-level resistance emerging after drug exposure) subpopulations were measured and optimal PK/PD targets for reducing both ARS and HRS were determined. Cumulative fractional response (CFR) was calculated with Monte Carlo simulation for 9 MU q24h, 4.5 MU q12h and 3 MU q8h clinical dosing regimens.

A 2–5 logc.f.u. ml decrease of the total bacterial population was observed within the first 2 h of exposure, followed by regrowth at 12 h. Colistin exposure was positively and negatively correlated with HRS and ARS 24–0 h c.f.u. ml changes, respectively. An optimal PK/PD (~0.5log increase) target of 35 fAUC/MIC (the ratio of the area under the unbound concentration–time curve to the MIC) was found for reducing both HRS and ARS of high-level resistance (MIC >16 mg l). The 4.5 MU q12h regimen had slightly higher CFR (74 %) compared to the other dosing regimens.

High colistin exposures reduced high-level adaptive resistance at the expense of selection of heteroresistant subpopulations.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): adaptive resistance , colistin , heteroresistance , K. pneumoniae and PK/PD modelling
© 2022 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001565
2022-10-06
2024-05-02
Loading full text...

Full text loading...

References

  1. Giamarellou H, Elsevier BV. Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Int J Antimicrob Agents 2010; 36 Suppl 2:S50–4 [View Article]
     [Google Scholar]
  2. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012; 25:682–707 [View Article]
     [Google Scholar]
  3. Ferranti M, Schiaroli E, Palmieri MI, Repetto A, Vecchiarelli A et al. Carbapenemase-producing Enterobacteriaceae isolates resistant to last-line antibiotics in an Italian general hospital. New Microbiol 2018; 41:274–281
     [Google Scholar]
  4. Baron S, Hadjadj L, Rolain JM, Olaitan AO. Molecular mechanisms of polymyxin resistance: knowns and unknowns. Int J Antimicrob Agents 2016; 48:583–591 [View Article]
     [Google Scholar]
  5. Zavascki AP, Girardello R, Magagnin CM, Antochevis LC, Maciel RA et al. Emergence of polymyxin B resistance in a polymyxin B-susceptible KPC-producing Klebsiella pneumoniae causing bloodstream infection in a neutropenic patient during polymyxin B therapy. Diagn Microbiol Infect Dis 2018; 90:134–138 [View Article]
     [Google Scholar]
  6. Karakonstantis S, Saridakis I. Colistin heteroresistance in Acinetobacter spp.: systematic review and meta-analysis of the prevalence and discussion of the mechanisms and potential therapeutic implications. Int J Antimicrob Agents 2020; 56:106065 [View Article]
     [Google Scholar]
  7. Srinivasan VB, Rajamohan G. KpnEF, a new member of the Klebsiella pneumoniae cell envelope stress response regulon, is an SMR-type efflux pump involved in broad-spectrum antimicrobial resistance. Antimicrob Agents Chemother 2013; 57:4449–4462 [View Article]
     [Google Scholar]
  8. Olaitan AO, Morand S, Rolain J-M. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol 2014; 5:643 [View Article]
     [Google Scholar]
  9. Jayol A, Nordmann P, Brink A, Villegas M-V, Dubois V et al. High-level resistance to colistin mediated by various mutations in the crrB gene among carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2017; 61:e01423-17 [View Article]
     [Google Scholar]
  10. Cain AK, Boinett CJ, Barquist L, Dordel J, Fookes M et al. Morphological, genomic and transcriptomic responses of Klebsiella pneumoniae to the last-line antibiotic colistin. Sci Rep 2018; 8:9868 [View Article]
     [Google Scholar]
  11. Cheng YH, Lin TL, Lin YT, Wang JT. A putative RND-type efflux pump, H239_3064, contributes to colistin resistance through CrrB in Klebsiella pneumoniae. J Antimicrob Chemother 2018; 73:1509–1516 [View Article]
     [Google Scholar]
  12. Andersson DI, Nicoloff H, Hjort K. Mechanisms and clinical relevance of bacterial heteroresistance. Nat Rev Microbiol 2019; 17:479–496 [View Article]
     [Google Scholar]
  13. Rojas LJ, Salim M, Cober E, Richter SS, Perez F et al. Colistin resistance in carbapenem-resistant Klebsiella pneumoniae: laboratory detection and impact on mortality. Clin Infect Dis 2017; 64:711–718 [View Article]
     [Google Scholar]
  14. Weinstein MP, Patel JB, Bobenchik AM, Campeau S, Cullen SK et al. M100 performance standards for antimicrobial susceptibility testing A CLSI supplement for global application. Performance Standards for Antimicrobial Susceptibility Testing Performance Standards for Antimicrobial Susceptibility Testing 2020
     [Google Scholar]
  15. Meletiadis J, Al-Saigh R, Velegraki A, Walsh TJ, Roilides E et al. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro Pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2012; 56:403–410 [View Article]
     [Google Scholar]
  16. Vourli S, Tsala M, Kotsakis S, Daikos GL, Tzouvelekis L et al. Comparison of short versus prolonged infusion of standard dose of meropenem against carbapenemase-producing Klebsiella pneumoniae isolates in different patient groups: a pharmacokinetic-pharmacodynamic approach. J Pharm Sci 2016; 105:1513–1518 [View Article]
     [Google Scholar]
  17. Daikos GL, Skiada A, Pavleas J, Vafiadi C, Salatas K et al. Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use. J Chemother 2010; 22:175–178 [View Article]
     [Google Scholar]
  18. Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 2012; 56:4241–4249 [View Article]
     [Google Scholar]
  19. Tsala M, Vourli S, Georgiou P-C, Pournaras S, Tsakris A et al. Exploring colistin pharmacodynamics against Klebsiella pneumoniae: A need to revise current susceptibility breakpoints. J Antimicrob Chemother 2018; 73:953–961 [View Article] [PubMed]
     [Google Scholar]
  20. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005; 55:601–607 [View Article]
     [Google Scholar]
  21. El-Sayed Ahmed MAE-G, Zhong L-L, Shen C, Yang Y, Doi Y et al. Colistin and its role in the era of antibiotic resistance: an extended review (2000-2019). Emerg Microbes Infect 2020; 9:868–885 [View Article]
     [Google Scholar]
  22. Liao W, Lin J, Jia H, Zhou C, Zhang Y et al. Resistance and Heteroresistance to colistin in Escherichia coli isolates from Wenzhou, China. Infect Drug Resist 2020; 13:3551–3561 [View Article]
     [Google Scholar]
  23. Mashaly GES, Mashaly MES. Colistin-heteroresistance in carbapenemase-producing enterobacter species causing hospital-acquired infections among egyptian patients. J Glob Antimicrob Resist 2021; 24:108–113 [View Article]
     [Google Scholar]
  24. EUCAST Colistin Breakpoints – guidance document 2021 [Internet]; 2021 https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Guidance_documents/Colistin_guidance_2021.pdf
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001565
Loading
Pharmacodynamics of colistin resistance in carbapenemase-producing Klebsiella pneumoniae: the double-edged sword of heteroresistance and adaptive resistance
J. Med. Microbiol. 71, 001565 (2022); https://doi.org/10.1099/jmm.0.001565
/content/journal/jmm/10.1099/jmm.0.001565
/content/journal/jmm/10.1099/jmm.0.001565
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error